ReviewFrontiers in cell and developmental biology2026
Telomere-driven dysfunctional changes in gynecological cancers: mechanistic insights, biomarker potential, and therapeutic targeting.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Telomeres are major determinants of chromosome integrity, and when poorly regulated, they have been shown to contribute critically to malignant transformation. However, in gynaecological malignancies, telomeres are interpreted inconsistently and have yet to be smoothly incorporated into diverse disease types. The review incorporates the existing evidence of the relationship between telomere dysfunction and the evolution of cervical, ovarian, endometrial, vulvar, and vaginal cancer. The review discusses the joint causes of telomere erosion, defective capping, defective integrity, and dysregulated telomerase activity in gynaecological cancer development, and the ensuing genomic instability, disruption in tissue homeostasis, inflammation, immune evasion, clonal evolution, and changes in individual organ physiology. According to this integrative framework, there are common and cancer-specific processes, new biomarkers for telomere maintenance, and therapeutic prospects focused on telomere maintenance pathways. The development of standardized, longitudinal methodologies will be key to translating telomere biology into clinically actionable approaches in gynaecological oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.